Glucocorticoids and lung development in the fetus and preterm infant

Pediatric Pulmonology

Volumn 32, Issue 1, 2001, Pages 76-91

  Bolt, Roel J ^a   van Weissenbruch, M M ^a   Lafeber, H N ^a   Delemarre van de Waal, H A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bronchopulmonary dysplasia; Chronic lung disease of newborns; Cytokines; Fetus; Glucocorticoid; Inflammation; Lung development; Neonatology; Neurologic complications; Prematurity; Preterm

Indexed keywords

ANTIOXIDANT; CHEMOKINE; CYTOKINE; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUNG SURFACTANT; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; TRANSCRIPTION FACTOR;

ARTICLE; ARTIFICIAL VENTILATION; CELL DIFFERENTIATION; CELL MATURATION; CYTOKINE PRODUCTION; DNA SYNTHESIS INHIBITION; FETUS; FETUS LUNG; HUMAN; INFLAMMATORY CELL; LUNG ALVEOLUS SURFACE TENSION; LUNG DEVELOPMENT; LUNG DYSPLASIA; LUNG FLUID; LUNG INFECTION; NEWBORN; PHOSPHOLIPID SYNTHESIS; PREMATURITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RESPIRATORY DISTRESS SYNDROME; SEPSIS; SIDE EFFECT;

FEMALE; FETAL ORGAN MATURITY; FETUS; GLUCOCORTICOIDS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; LUNG; PREGNANCY; PULMONARY SURFACTANTS; RECEPTORS, GLUCOCORTICOID;

EID: 0034954680     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.1092     Document Type: Article

References (256)

1. The role of cortisol in preparing the fetus for birth
2. Regulation of fetal lung maturation
3. The placenta as hypothalamus and pituitary: Possible impact on maternal and fetal adrenal function
4. Neuroendocrine regulation of pituitary-adrenal function during fetal life
5. Developmental and functional biology of the primate fetal adrenal cortex
6. Fetal lung maturation
7. DNA binding of the glucocorticoid receptor is not essential for survival
8. Human SP-A1 and SP-A2 genes are differentially regulated during development and by cAMP and glucocorticoids
9. Glucocorticoid regulation of surfactant components in immature lambs
10. Lung development
11. The development of large and small airways
12. Extracellular matrix and the regulation of lung development and repair
13. Programmed cell death contributes to postnatal lung development
14. Development of mucus-secreting elements
15. Distribution and number of Clara cells in the normal and disturbed development of the human fetal lung
16. Surfactant proteins: Molecular genetics of neonatal pulmonary diseases
17. Surfactant peptides stimulate uptake of phosphatidylcholine by isolated cells
18. Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice
19. Primary surfactant deficiency
20. Inherited surfactant protein B deficiency
21. Neonatal respiratory distress in near-term infants - Consider surfactant protein B deficiency
22. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds
23. Aberrant processing of surfactant protein C in hereditary SP-B deficiency
24. Reduced SP-C expression in full term infants with RDS
25. Altered surfactant function and structure in SP-A gene targeted mice
26. Surfactant metabolism in surfactant protein A-deficient mice
27. Surfactant protein A-deficient mice are susceptible to group B streptococcal infection
28. Collectins and pulmonary host defense
29. Pulmonary cell biology
30. Expression of type 2 11beta-hydroxysteroid dehydrogenase and corticosteroid hormone receptors in early human fetal life
31. The glucocorticoid receptor gene is in 5q31-q32
32. Assignment of the human gene encoding the glucocorticoid receptor to the q11-q13 region on chromosome 5
33. Primary structure and expression of a functional human glucocorticoid receptor cDNA
34. Expression and subcellular distribution of the beta-isoform of the human glucocorticoid receptor
35. The human glucocorticoid receptor b isoform. Expression, biochemical properties, and putative function
36. Enhancer elements activated by steroid hormones?
37. Glucocorticoids: Mechanisms of action and anti-inflammatory potential in asthma
38. Steroid hormone receptors: Interaction with deoxyribonucleic acid and transcription factors
39. Gene regulation by steroid hormones
40. Glucocorticolds and fetal programming
41. Glucocorticoid and estradiol receptors in human fetal lung
42. Glucocorticoid receptor concentrations in human lung at different growth stages
43. Glucocorticoid receptor localization in normal and asthmatic lung
44. Premature parturition after infusion of corticotrophin or cortisol into foetal lambs
45. Premature delivery of foetal lambs, infused with glucocorticoids
46. A controlled trail of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants
47. Antenatal corticosteroid therapy: A meta-analysis of the randomized trails, 1972 to 1994
48. Prophylactic corticosteroids for preterm birth
49. Hormonal regulation of pulmonary surfactant
50. Impact of advances in physiology, biochemistry, and molecular biology on pulmonary disease in neonates
51. Chronic lung disease: The role of oxidative stress
52. The glucocorticoid-glucocorticoid receptor signal transduction pathway, transforming growth factor-beta, and embryonic mouse lung development
53. Effects of antenatal and postnatal corticosteroids on the preterm lung
54. Antenatal betamethasone therapy augments nitric oxide-mediated relaxation of preterm ovine pulmonary veins
55. Central integrative role of oestrogen in modulating the communication between the placenta and fetus that results in primate fetal-placental development
56. Physiologic programming of the fetus
57. Prenatal dexamethasone and exogenous surfactant therapy: Surface activity and surfactant components in airway specimens
58. Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome
59. Surfactant phosphatidylcholine composition during dexamethasone treatment in chronic lung disease
60. Regulation of surfactant protein D in human fetal lung
61. Regulation of mRNA's for the hydrophobic surfactant proteins in the human lung
62. The combined effects of insulin and cortisol on surfactant protein mRNA levels
63. Glucocorticoid enhances surfactant proteolipid Phe and pVal synthesis and mRNA in fetal lung
64. Androgens delay human fetal lung maturation in vitro
65. Corticosteroid stimulation of phosphatidylcholine synthesis in cultured fetal rabbit lung. Evidence for de novo protein synthesis mediated by glucocorticoid receptors
66. Fetal lung maturation
67. Fetal versus maternal and gestational age effects of repetitive antenatal glucocorticoids
68. Cloning and expression of glucocorticoid-induced genes in fetal rat lung fibroblsts. Transforming growth factor-beta 3
69. Postnatal development of alveoli. Regulation and evidence for a critical period in rats
70. Proliferation and differentiation defects during lung development in corticotropin-releasing hormone-deficient mice
71. Regulation of expression of aminopeptidase N in fetal rat lung by dexamethasone and epidermal growth factor
72. Corticosteroids, thyrotropin-releasing hormone, and antioxidant enzymes in preterm lamb lungs
73. Prenatal glucocorticoid and T4 effects on lung morphology in preterm lambs
74. Betamethasone and the rhesus fetus: Effect on lung morphometry and connective tissue
75. Lung morphometry and collagen and elastin content: Changes during normal development and after prenatat hormone exposure in sheep
76. New approches to hormonal acceleration of fetal lung maturation
77. Autoradiographic localization of specific [3H]dexamethasone binding in fetal lung
78. Collagen and elastin in rabbit fetal lung: Ontogeny and effects of steroids
79. Glucocorticoids upregulate tropoelastin expression during late stages of fetal lung development
80. Steroid effects on lung collagen and elastin are dependent on gestational age
81. Regulation of the epidermal growth factor receptor in fetal rat lung fibroblasts during late gestation
82. Identification of a negative glucocorticoid response element in the rat type 1 vasoactive intestinal polypeptide receptor gene
83. Glucocorticoid regulation of ornithine decarboxylase in the postnatal rat lung
84. The cellular mechanism of glucocorticoid acceleration of fetal lung maturation
85. Development of fibroblast-type-II cell communications in fetal rabbit lung organ culture
86. Epithelial-interstitial cell interactions in fetal rat lung development accelerated by steroids
87. Hypophysectomy and porcine fetal lung development
88. Perinatal rat lung catalase gene expression: Influence of corticosteroid and hyperoxia
89. Effects of oxygen on the newborn
90. Repetitive prenatal glucocorticoid therapy reduces oxidative stress in the lungs of preterm lambs
91. Higher lung antioxidant enzyme activity persists after single dose of corticosteroids in preterm lambs
92. Antioxidant enzyme responses to hyperoxia in preterm and term rats after prenatal dexamethasone administration
93. Prenatal dexamethasone treatment improves survival of newborn rats during prolonged high oxygen exposure
94. Corticosteroids and surfactant change lung function and protein leaks in the lungs of ventilated premature rabbits
95. Postnatal lung function and protein permeability after fetal or maternal corticosteroids in preterm lambs
96. Antenatal betamethasone therapy augments isoproterenol and prostaglandin E2-mediated relaxation of preterm ovine pulmonary veins
97. A single dose of antenatal betamethasone enhances isoprenaline and prostaglandin E2-induced relaxation of preterm ovine pulmonary arteries
98. Glucocorticoid regulation of epithelial sodium channel gene in human fetal lung
99. Aquaporin-1 water channel protein in lung: Ontogeny, steroid-induced expression, and distribution in rat
100. Fetal pulmonary beta-adrenergic receptors: Characterization in the human and in vitro modulation by glucocorticoids in the rabbit
101. Glucocorticoids preferentially increase fetal alveolar b-adrenoreceptors: Autoradiographic evidence
102. Regulation of neonatal rat lung compliance by beta-adrenergic receptor stimulation: Effects of prenatal exposure to terbutaline or dexamethasone
103. Pulmonary disease following respiratory therapy of hyaline membrane disease: Bronchopulmonary dysplasia
104. Bronchopulmonary dysplasia
105. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease
106. Abnormal pulmonary outcomes in premature infants: Prediction from oxygen requirement in the neonatal period
107. A typical chronic lung disease patterns in neonates
108. Outcome of respiratory distress syndrome at 28 days: A prospective longitudinal study
109. Respiratory tract disorders in the fetus and neonates
110. Dexamethasone and hypertension in preterm infants
111. Pathologic features of long standing "healed" bronchopulmonary dysplasia: A study of 28 3-40 month old infants
112. Morphometric analysis of the lung in bronchopulmonary dysplasia
113. Airway size and structure in the normal fetus and infant lung and the effect of premature delivery and artificial ventilation
114. Ventilator-related pathology in the extremely immature lung
115. Evolution and natural history of chronic lung disease of prematurity
116. The effects of preterm delivery and mechanical ventilation on human lung growth
117. Pulmonary vascular damage and the development of cor pulmonale following hyaline membrane disease
118. Respiratory disorders of the neonate
119. Pathophysiology and treatment of bronchopulmonary dysplasia
120. Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: A sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates
121. Chronic lung disease following neonatal ventilation I: Incidence in two geographically defined populations
122. Role of Ureaplasma urealyticum in lung disease of prematurity
123. Risk factors for chronic lung disease in the surfactant era: A North Carolina population-based study of very low birth weight infants
124. Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease?
125. The adenovirus and bronchopulmonary dysplasia: An association that could be causal or coincidental
126. Link between early adrenal function and respiratory outcome in preterm infants: Airway inflammation and patent ductus arteriosus
127. Inflammatory mechanisms in neonatal chronic lung disease
128. Markers and mediators of inflammation in neonatal lung disease
129. Pathophysiology of the lung injury and repair: Special features of the immature lung
130. Comparison of pulmonary inflammatroy mediators in preterm infants treated with intermittent positive pressure ventilation or high frequency oscillatory ventilation
131. Lung cytokines and ARDS
132. Bronchial epithelium: Morphology, function and pathophysiology in asthma
133. Expression and generation of interleukin-8, IL-6 and granulocyte colony-stimulating factor by bronchial epithelial cells and enhancement by IL-1b and tumour necrosis factor-a
134. Corticosteroids differentially regulate secretion of IL-6, IL-8, and G-CSF by a human bronchial epithelial cell line
135. Differential cytokine mRNA expression by neonatal pulmonary cells
136. Inflammatory cells in the lungs of premature infants on the first day of life: Perinatal risk factors and origin of cells
137. Newborn tracheal aspirate cytology: Classification during respiratory distress syndrome and bronchopulmonary dysplasia
138. Tracheal aspirate cytology and bronchopulmonary dysplasia
139. Early prediction of chronic lung disease by tracheal aspirate cytology in ventilated newborns
140. Increase in interlukin-8 and soluble intercellular adhesion molucule-1 in bronchoalveolar lavage in fluid from premature infants who develop chronic lung disease
141. Increase in interleukin (IL)-1b and IL-6 in bronchoalveolar lavage fluid obtained from infants with chronic lung disease of prematurity
142. Increased activity of interleukin-6 but not tumor necrosis factor-a in lung lavage of premature infants is associated with the development of bronchopulmonary dysplasia
143. Potential role of interleukin-1 in the development of bronchopulmonary dysplasia
144. Increased levels of bronchoalveolar lavage fluid interlukin-6 in preterm ventilated infants after prolonged rupture of membranes
145. Undetectable interleukin (IL)-10 and persistent IL-8 expression early in hyaline membrane disease: A possible developmental basis for the predisposition to chronic lung inflammation in preterm newborns
146. Measurement of interleukin 10 in bronchoalveolar lavage from preterm ventilated preterm infants
147. Can we make sense out of cytokines?
148. The effects of IL-10 on proinflammatory cytokine expression (II-1beta and IL-8) in hyaline membrane disease (HMD)
149. Anti-inflammatory cytokines
150. Anti-inflammatory actions of steroids: Molecular mechanisms
151. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis
152. Molecular mechanisms of steroid action in asthma
153. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation
154. NF-kappa B: A pleiotropic mediator of inducible and tissue-specific gene control
155. Antitumor promotion and antiinflammation: Down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone
156. Structure, regulation and function of NF-kappa B
157. Novel mechanism of glucocorticoid-mediated gene expression
158. Negative cross-talk between Re1A and the glucocorticoid receptor: A possible mechanism for the antiinflammatory action of glucocorticoids
159. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids
160. Dexamethasone effects on lung function and riks in three week old ventilator dependent preterm infants
161. Cytokines in chronic lung disease of prematurity
162. Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease
163. Effect of dexamethasone on pulmonary inflammation and pulmonary function of ventilator-dependent infants with bronchopulmonary dysplasia
164. Tumour necrosis factor in the bronchoalveolar secretions of infants with respiratory distress syndrome and the effect of dexamethasone treatment
165. Dexamethasone modulation of tumour necrosis factor-a (cachectin) release by activated normal human alveolar macrophages
166. Dexamethasone treatment of infants at risk for chronic lung disease: Surfactant components and inflammatory parameters in airway specimens
167. L-selectin expression on polymorphonuclear leukocytes and monocytes in premature infants: Reduced expression after dexamethasone treatment for bronchopulmonary dysplasia
168. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia
169. Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant
170. Dexamethasone therapy in neonatal chronic lung disease: An international placebo-controlled trial
171. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia
172. Dexamethasone therapy for chronic lung disease in ventilator-and respirator-dependent infants: A controlled trial
173. Dexamethsone effects on the hospital course of infants with bronchopulmonary dysplasia who are dependent on artificial ventilation
174. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia
175. Dexamethasone in neonatal chronic lung disease: Pulmonary effects and intracranial complications
176. Randomized controlled trial of dexamethasone treatment in very low birthweight infants with ventilatory dependant chronic lung disease
177. Controlled trial of dexamethasone in neonatal chronic lung disease: A 3 year follow up
178. Chronic lung disease of prematurity: Are we too cautious with steroids?
179. Repeated antenatal corticosteroids: Size at birth and subsequent development
180. Antenatal glucocorticoids and programming of the developing CNS
181. Antenatal steroids and the developing brain
182. The effectiveness and side effects of dexamethasone in preterm infants with bronchopulmonary dysplasia
183. Two doses of early intravenous dexamethasone for prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome
184. Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: A multicenter clinical trial
185. Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome
186. Early dexamethasone (D) therapy in surfactant pretreated infants: Effects in infants <1000 g
187. Effect of dexamethasone (D) therapy on renal function in VLBW infants with RDS
188. Effects of early dexamethasone administration on respiratory outcome in VLBW infants with respiratory distress syndrome (RDS) treated with surfactant (S)
189. Effects of early dexamethasone therapy on pulmonary mechanics in preterm infants: A randomized trial
190. Dexamethasone therapy in infants at risk for chronic lung disease (CLD): A multi-center, randomized, double-masked trial
191. Comparitive efficacy of early (day 4) versus late (day 14) dexamethasone (dex) therapy in ventilator dependent infants with birthweight <1000 grams
192. Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: A double blind, controlled study
193. Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: A randomized, controlled trial
194. Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants
195. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants
196. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants
197. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants
198. Antioxidants in neonatal lung disease
199. Triamcinolone-induced structural alterations in the development of the lung of the fetal rhesus macaque
200. Formation of alveoli in rats: Postnatal effect of prenatal dexamethasone
201. Effects of postnatal dexamethasone treatment on the development of alveoli in adult rats
202. Alveolar dimensions and number: Developmental and hormonal regulation
203. Influence of postnatally administered glucocorticoids on rat lung growth
204. Formation of pulmonary alveoli and gas-exchange surface area: Quantitation and regulation
205. Normal lung growth following antenatal dexamethasone treatment for respiratory distress syndrome
206. Decreased alveolisation in baboon survivors with bronchopulmonary dysplasia
207. Lung function in children of low birth-weight
208. Respiratory health and lung function in 8-year-old children of very low birth weight: A cohort study
209. The long-term pulmonary sequelae of prematurity: The role of familial airway reactivity and the respiratory distress syndrome
210. Lung function eight years after neonatal ventilation
211. Antenatal dexamethasone and subsequent lung growth
212. Single and repetive maternal glucocorticoid exposures reduce fetal growth in sheep
213. Repetitive prenatal glucocorticoids improve lung function and decrease growth in preterm lambs
214. The influence of betamethasone and dexamethasone on motor development in young rats
215. Neurotoxicity of glucocorticoids in the primate brain
216. Antenatal corticosteroids and cranial ultrasonographic abnormalities
217. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants
218. Postnatal steroids: Short-term gain, long-term pain?
219. Perinatal treatment with glucocorticoids and the risk of maldevelopment of the brain
220. Early dexamethasone therapy in preterm infants: A follow-up study
221. Randomized placebo controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: Outcome of study participants at 1-year adjusted age
222. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy
223. Regulation of the primate fetal adrenal cortex
224. Discordant accelerated pulmonary maturation after adrenocorticotropic hormone-induced labor in twin sheep fetuses
225. Molecular genetic analysis of glucocorticoid signalling in development
226. Metyrapone delays surfactant and antioxidant enzyme maturation in developing rat lung
227. Adrenal status during the first month of life in mature and premature human infants
228. Hypothalamic pituitary adrenal function in the extremely low birth weight infant
229. Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia
230. Variability of plasma cortisol levels in extremely low birth weight infants
231. Longitudinal study of plasma ACTH and cortisol in very low birth weight infants in the first 8 weeks of life
232. Effect of gestational age, postnatal age, and illness on plasma cortisol concentrations in premature infants
233. Serum adrenal steroid concentrations in premature infants
234. Corticosteroid binding globulin, total serum cortisol, and stress in extremely low-birth-weight infants
235. Glucocorticoid-responsive hypotension in extremely low birth weight newborns
236. Addisonian crisis in extremely premature neonates
237. Single dose dexamethasone treatment of hypotension in preterm infants
238. Differences in response to low-dose ACTH stimulation tests in preterm infants with increasing gestational age
239. Serum concentrations of cortisone and cortisol in premature infants
240. Adrenal steroidogenesis in very low birth weight preterm infants
241. Plasma mineralocorticoids, glucocorticoids and progestins in premature infants: Longitudinal study during the first week of life
242. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants
243. Antenatal glucocorticoid therapy: A caveat to the applause
244. Glucocorticoids in perinatal medicine: Misguided rockets?
245. Early production of macrophage inflammatory protein-1a occurs in respiratory distress syndrome and is associated with poor outcome
246. Bronchoalveolar interleukin-1b in infants on day 1 of life
247. Randomised trial of erythromycin on the development of chronic lung disease in preterm infants
248. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops
249. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less
250. Tracheal aspirate interleukin-8 (IL-8) elevation followed by interleuking-6 (IL-6) precede the appearance of neutrophils (PML) in preterm neonates who develop bronchopulmonary dysplasia (BPD)
251. Role of elevated plasma soluble ICAM-1 and bronchial lavage fluid IL-8 levels as markers of chronic lung disease in premature infants
252. Interleukin 8 and granulocyte elastase in the tracheobronchial aspirate of infants without respiratory distress syndrome or intrauterine infection and development of chronic lung disease
253. Interleukin 8 and granulocyte elastase alpha 1 proteinase inhibitor complex in the tracheobronchial aspirates of infants with chronic lung disease following respiratory distress syndrome
254. Markers of pulmonary inflammation in tracheobronchial fluid of premature infants with respiratory distress syndrome
255. Increase in the concentration of transforming growth factor beta-1 in bronchoalveolar lavage fluid before the development of chronic lung disease of prematurity